Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank67
3Y CAGR+52.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+52.2%/yr
vs -33.6%/yr prior
Acceleration
+85.8pp
Accelerating
Percentile
P67
Within normal range
vs 3Y Ago
3.5x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 16.57% |
| Q3 2025 | -15.20% |
| Q2 2025 | -13.67% |
| Q1 2025 | 20.13% |
| Q4 2024 | -2.51% |
| Q3 2024 | 12.92% |
| Q2 2024 | -5.73% |
| Q1 2024 | 11.53% |
| Q4 2023 | -8.68% |
| Q3 2023 | 29.13% |
| Q2 2023 | 27.80% |
| Q1 2023 | 44.93% |
| Q4 2022 | 4.70% |
| Q3 2022 | -1.36% |
| Q2 2022 | 12.44% |
| Q1 2022 | 2.84% |
| Q4 2021 | -33.98% |
| Q3 2021 | 3.21% |
| Q2 2021 | 41.59% |
| Q1 2021 | -20.58% |
| Q4 2020 | -6.02% |
| Q3 2020 | 21.15% |
| Q2 2020 | 35.84% |
| Q1 2020 | -2.51% |
| Q4 2019 | 15.58% |
| Q3 2019 | 17.75% |
| Q2 2019 | 22.64% |
| Q1 2019 | 0.00% |